Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences PR Newswire LUND, Sweden, April 1, 2022 LUND...
Alligator Bioscience Announces Completion of 600 mg Dose Cohort for ATOR-1017, Dose-escalation and Enrollment for 900 mg dose Cohort Commences PR Newswire LUND, Sweden, April 1, 2022 LUND...
Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg PR Newswire LUND, Sweden, March 23, 2022 LUND, Sweden, March...
Alligator Bioscience Announces mitazalimab OPTIMIZE-1 Trial Update: Successful Completion of Phase Ib, Phase II enrolling at 900 µg/kg PR Newswire LUND, Sweden, March 23, 2022 LUND, Sweden, March...
Alligator Bioscience AB: Year End report January-December 2021 PR Newswire STOCKHOLM, Feb. 11, 2022 STOCKHOLM, Feb. 11, 2022 /PRNewswire/ -- OPTIMIZE-1 Phase II - On Track and Moving...
Alligator Bioscience AB: Year End report January-December 2021 PR Newswire STOCKHOLM, Feb. 11, 2022 STOCKHOLM, Feb. 11, 2022 /PRNewswire/ -- OPTIMIZE-1 Phase II - On Track and Moving...
Alligator Bioscience Appoints Sumeet Ambarkhane MD as Chief Medical Officer PR Newswire LUND, Sweden, Feb. 1, 2022 LUND, Sweden, Feb. 1, 2022 /PRNewswire/ -- Alligator Bioscience (Nasdaq...
Alligator Bioscience Appoints Sumeet Ambarkhane MD as Chief Medical Officer PR Newswire LUND, Sweden, Feb. 1, 2022 LUND, Sweden, Feb. 1, 2022 /PRNewswire/ -- Alligator Bioscience (Nasdaq...
Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty PR Newswire LUND, Sweden, Jan. 19, 2022 LUND, Sweden...
Alligator Bioscience Announces Commencement of a Sponsored Research Agreement with the University of Pennsylvania Led by Dr. Gregory Beatty PR Newswire LUND, Sweden, Jan. 19, 2022 LUND, Sweden...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 23 | 23 | 23 | 2768 | 23 | DE |
4 | 0 | 0 | 23 | 23 | 23 | 5401 | 23 | DE |
12 | 0 | 0 | 23 | 23 | 23 | 2201 | 23 | DE |
26 | 0 | 0 | 23 | 23 | 23 | 1521 | 23 | DE |
52 | 0 | 0 | 23 | 23 | 23 | 2244 | 23 | DE |
156 | 0 | 0 | 23 | 23 | 23 | 1418 | 23 | DE |
260 | 0 | 0 | 23 | 23 | 23 | 1672 | 23 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales